Login
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
South America
Harvard
Social Media
Formula 1
Donald Trump
Artificial Intelligence
Natural Disasters
Premier League
Latin America
European Union
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma

Summary by oncnursingnews.com
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
oncnursingnews.comoncnursingnews.com

Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma

CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

oncnursingnews.com broke the news in on Tuesday, May 20, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal